Cormedix(DE:19KA)
€4.66-0.01 (-0.30%)
DE:19KA
Cormedix stock drug pipeline
€4.66
At close:-0.01 (-0.30%)
Cormedix (19KA) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Heparin, (Taurolidine And Heparin) Catheter Lock Solution | Central Line Associated Blood Stream Infections (Clabsi) | Phase III | Recruiting | Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) | Jan 15, 2025 | ― |
| Standard of Care, (Taurolidine And Heparin) Catheter Lock Solution | Catheter-Related Infections | Phase IV | Recruiting | Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age | Dec 02, 2024 | ― |
| Heparin, Neutrolin | Kidney Failure, Chronic, Catheter-Related Infections | Phase III | Completed | Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection | Jan 07, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Heparin, (Taurolidine And Heparin) Catheter Lock Solution | Phase III | Central Line Associated Blood Stream Infections (Clabsi) | Recruiting | Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) | Jan 15, 2025 | ― |
| Standard of Care, (Taurolidine And Heparin) Catheter Lock Solution | Phase IV | Catheter-Related Infections | Recruiting | Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age | Dec 02, 2024 | ― |
| Heparin, Neutrolin | Phase III | Kidney Failure, Chronic, Catheter-Related Infections | Completed | Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection | Jan 07, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cormedix Inc. (DE:19KA) have in its pipeline
Cormedix DE:19KA is currently developing the following drugs: Heparin, (Taurolidine And Heparin) Catheter Lock Solution, Standard of Care, (Taurolidine And Heparin) Catheter Lock Solution, Heparin, Neutrolin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
